Elanco Animal Health Incorporated Cash and Restricted Cash
Elanco Animal Health Incorporated (ELAN) had Cash and Restricted Cash of $530.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $530.00M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $428.00M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $545.00M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $505.00M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $530.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $428.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $545.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $505.00M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $539.00M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $487.00M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $468.00M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $490.00M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $416.00M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $345.00M 10-Q · filed 2025-05-07 | |
| 2023-12-31 | $352.00M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $369.00M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $367.00M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $318.00M 10-Q · filed 2024-05-08 | |
| 2022-12-31 | $345.00M 10-K · filed 2026-02-24 | |
| 2022-09-30 | $460.00M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $507.00M 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $342.00M 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $638.00M 10-K · filed 2025-02-25 | |
| 2021-09-30 | $453.00M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $580.00M 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $515.00M 10-Q · filed 2022-05-09 | |
| 2020-12-31 | $506.00M 10-K · filed 2024-02-26 | $505.40M 10-K · filed 2021-03-01 |
| 2020-09-30 | $671.00M 10-Q · filed 2021-11-05 | $670.60M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $1.40B 10-Q · filed 2021-08-09 | $1.40B 10-Q · filed 2020-07-30 |
| 2020-03-31 | $1.22B 10-Q · filed 2021-05-07 | $1.22B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $345.00M 10-K · filed 2023-03-01 | $345.10M 10-K · filed 2020-02-28 |
| 2019-09-30 | $320.30M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $396.60M 10-Q · filed 2020-07-30 | |
| 2019-03-31 | $300.60M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $678.00M 10-K · filed 2022-02-28 | $677.50M 10-K · filed 2019-02-20 |
| 2018-09-30 | $934.90M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $321.00M 10-Q · filed 2019-08-13 | |
| 2018-03-31 | $263.40M 10-Q · filed 2019-05-14 | |
| 2017-12-31 | $323.40M 10-K · filed 2021-03-01 | |
| 2017-09-30 | $343.60M 10-Q · filed 2018-11-08 | |
| 2016-12-31 | $258.80M 10-K · filed 2020-02-28 | |
| 2015-12-31 | $460.60M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |